Hospital Pharmacy - June 2018 - 159
159
Vials of 500 mg, 1 g, and 2 g: reconstitute
with 10-mL SWFI to resulting
concentrations of 50, 95, and 180 mg/mL,
respectively
No further dilution required
Maximum concentration for IV push is 200
mg/mL in SWFI65
Vials of 1 and 2 g: reconstitute with 10-mL
and 10- to 20-mL SWFI to resulting
concentrations of 95 mg/mL and 95 or 182
mg/mL, respectively
No further dilution required
Vials of 1 and 2 g: reconstitute with 10-mL
SWFI to resulting concentrations of 95
mg/mL and 180 mg/mL, respectively
No further dilution required
Fortaz vials of 500 mg, 1 g or 2 g:
reconstitute with 5.3-, 10-, and 10-mL
SWFI to resulting concentrations of 100,
100, and 170 mg/mL, respectively
Tazicef vials of 1 or 2 g: reconstitute with
10-mL SWFI to concentrations of 95 and
180 mg/mL, respectively
No further dilution required
Off-label preparation
McLaughlin 20172: 1 or 2 g diluted with 10
or 20 mL SWFI, respectively
** IV push
** Intermittent IV
infusion
** IM
** IV push
** Intermittent IV
infusion
** IM
** IV push
** Intermittent IV
infusion
** IV push
** Intermittent IV
infusion
** IM
Cefotaxime
Cefotetan
Cefoxitin
Ceftazidime
Cefepime
Off-label preparation
Tran 20173: 1- and 2-g doses diluted in NS
to a total volume of 10 mL
McLaughlin 20172: 1- and 2-g doses diluted in
10 and 20 mL of SWFI, respectively
Preparation
** Intermittent IV
infusion
** IM
Not approved for IV
push administration
Antibiotic
FDA-approved
administration
Table 1. (continued)
Reconstituted vials for Fortaz (all sizes):
12 h at RT or 3 d under refrigeration;
reconstituted solution in original
container may be frozen for 3 mo at
-20°C
Reconstituted vials for Tazicef (all sizes):
24 h at RT or 7 d under refrigeration;
reconstituted solution in original
container may be frozen for 3 mo at
-20°C
Polypropylene syringes, 100 and 200 mg/
mL in SWFI (Fortaz)63,86: 8 h at 22°C, 96
h at 4°C, and 91 d at -20°C
Reconstituted solutions in compatible
solutions: 24 h at 20 to 25°C and 7 d at 2
to 8°C (see PI for further details)
Polypropylene syringes, 100 and 200 mg/
mL in D5W, NS, or SWFI63,83,84: 14 d at
4°C, 1 d at RT, and up to 90 d at -20°C
Reconstituted vial: 24 h at RT, 7 d under
refrigeration, and 13 wk frozen for
500-mg and 1-g vials; 12 h at RT, 7 d
under refrigeration, and 13 wk frozen
for 2-g vial
Plastic syringe, reconstituted solutions for
IV push: 5 d under refrigeration and 13
wk frozen
Reconstituted vial: 24 h at 25°C, 96 h at
5°C, and 1 wk at -20°C
Plastic or glass syringes, reconstituted
solutions for IV push: 24 h at 25°C and
96 h at 5°C
Reconstituted vials with 1 g/10 mL
concentration: 6 h at RT and 1 wk under
refrigeration, for all compatible diluents
Plastic syringes, 1 and 2 g diluted in 10 mL
of SWFI63,81: 2 d at 24°C, 23 d at 4°C, 3
mo frozen at −15°C (time to 10% loss)
Stabilityb
IV push/IV slow injection
Inject over 3 to 5 min, directly into
vein or through the tubing of a
running compatible IV infusion
Off-label administration
McLaughlin 20172: Inject 1 g dose
over 2 min and 2 g dose over
5 min
Garrelts 198878: Inject over 1 to
2 min/g
Inject over 3 to 5 min, directly into
vein or through the tubing of a
running compatible IV infusion
Off-label administration
McLaughlin 20172: Inject over 5 min
Garrelts 198878: Inject over 1 to
2 min/g
Inject over 3 to 5 min
Inject over 3 to 5 min
Can be given directly into vein or
through the tubing of a running
compatible IV infusion60,63
Off-label administration
Tran 20173: Inject over 2 to 5 min
McLaughlin 20172: Inject over 5 min
Administration
(continued)
McLaughlin 20172: Evaluated use of IV push for
first dose only in ED
Garrelts 198878: Evaluated rates of postinfusion
phlebitis with IV push compared with IV
infusion in a tertiary hospital; 1 g diluted in
10 mL SWFI
Specific formulation of ceftazidime in Studies 1
and 2 not reported
McLaughlin 20172: evaluated use of IV push for
first dose only in ED; both 1 and 2 g doses
were diluted in 10 mL SWFI
Garrelts 198878: Evaluated rates of postinfusion
phlebitis with IV push compared with IV
infusion in a tertiary hospital; 1 g dose diluted
in 10 mL SWFI
Tran 2017 and McLaughlin 20172,3: Evaluated
use of IV push for first dose only in ED
An additional study85 evaluated 2 g over 3,
5, 10, and 15 min in healthy volunteers;
however, concentration was 40 mg/mL (total
volume, 50 mL)
Do not administer over <3 min; injection over
<1 min through a central venous catheter has
resulted in life-threatening arrhythmias
Maximum IV push concentration only reported
in Pediatric Injectable Drugs text
Notes
Table of Contents for the Digital Edition of Hospital Pharmacy - June 2018
Ed Board
TOC
USP <800>
Oct-Dec 2017 Boxed Warning Highlights approved by the FDA
Zoster Vaccine Recombinant, Adjuvanted
Multifactorial Causes of Tacrolimus Errors: Confusion With Strength/Formulation, Look-Alike Names, Preparation Errors, and More
New Medications in the Treatment of Nonalcoholic Steatohepatitis
One Chance for Your Best First Impression: Tips for New Pharmacists
Implications of Statin Use on Vasopressor Therapy in the Setting of Septic Shock
Intravenous Push Administration of Antibiotics: Literature and Considerations
The Role of Computerized Clinical Decision Support in Reducing Inappropriate Medication Administration During Epidural Therapy
Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study
Nonpharmacist Health Care Providers’ Knowledge of and Opinions Regarding Medication Costs in Critically Ill Patients
Detection of HBV, HCV, and Incidence of Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma–Treated Patients
Hospital Pharmacy - June 2018 - Cover1
Hospital Pharmacy - June 2018 - Cover2
Hospital Pharmacy - June 2018 - Ed Board
Hospital Pharmacy - June 2018 - TOC
Hospital Pharmacy - June 2018 - 131
Hospital Pharmacy - June 2018 - USP <800>
Hospital Pharmacy - June 2018 - 133
Hospital Pharmacy - June 2018 - Oct-Dec 2017 Boxed Warning Highlights approved by the FDA
Hospital Pharmacy - June 2018 - 135
Hospital Pharmacy - June 2018 - Zoster Vaccine Recombinant, Adjuvanted
Hospital Pharmacy - June 2018 - 137
Hospital Pharmacy - June 2018 - 138
Hospital Pharmacy - June 2018 - 139
Hospital Pharmacy - June 2018 - 140
Hospital Pharmacy - June 2018 - 141
Hospital Pharmacy - June 2018 - Multifactorial Causes of Tacrolimus Errors: Confusion With Strength/Formulation, Look-Alike Names, Preparation Errors, and More
Hospital Pharmacy - June 2018 - 143
Hospital Pharmacy - June 2018 - 144
Hospital Pharmacy - June 2018 - 145
Hospital Pharmacy - June 2018 - New Medications in the Treatment of Nonalcoholic Steatohepatitis
Hospital Pharmacy - June 2018 - 147
Hospital Pharmacy - June 2018 - One Chance for Your Best First Impression: Tips for New Pharmacists
Hospital Pharmacy - June 2018 - 149
Hospital Pharmacy - June 2018 - 150
Hospital Pharmacy - June 2018 - 151
Hospital Pharmacy - June 2018 - Implications of Statin Use on Vasopressor Therapy in the Setting of Septic Shock
Hospital Pharmacy - June 2018 - 153
Hospital Pharmacy - June 2018 - 154
Hospital Pharmacy - June 2018 - 155
Hospital Pharmacy - June 2018 - 156
Hospital Pharmacy - June 2018 - Intravenous Push Administration of Antibiotics: Literature and Considerations
Hospital Pharmacy - June 2018 - 158
Hospital Pharmacy - June 2018 - 159
Hospital Pharmacy - June 2018 - 160
Hospital Pharmacy - June 2018 - 161
Hospital Pharmacy - June 2018 - 162
Hospital Pharmacy - June 2018 - 163
Hospital Pharmacy - June 2018 - 164
Hospital Pharmacy - June 2018 - 165
Hospital Pharmacy - June 2018 - 166
Hospital Pharmacy - June 2018 - 167
Hospital Pharmacy - June 2018 - 168
Hospital Pharmacy - June 2018 - 169
Hospital Pharmacy - June 2018 - The Role of Computerized Clinical Decision Support in Reducing Inappropriate Medication Administration During Epidural Therapy
Hospital Pharmacy - June 2018 - 171
Hospital Pharmacy - June 2018 - 172
Hospital Pharmacy - June 2018 - 173
Hospital Pharmacy - June 2018 - 174
Hospital Pharmacy - June 2018 - 175
Hospital Pharmacy - June 2018 - 176
Hospital Pharmacy - June 2018 - Health Care Professionals Toward Adverse Drug Reaction Reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: A Cross-sectional Study
Hospital Pharmacy - June 2018 - 178
Hospital Pharmacy - June 2018 - 179
Hospital Pharmacy - June 2018 - 180
Hospital Pharmacy - June 2018 - 181
Hospital Pharmacy - June 2018 - 182
Hospital Pharmacy - June 2018 - 183
Hospital Pharmacy - June 2018 - 184
Hospital Pharmacy - June 2018 - 185
Hospital Pharmacy - June 2018 - 186
Hospital Pharmacy - June 2018 - 187
Hospital Pharmacy - June 2018 - Nonpharmacist Health Care Providers’ Knowledge of and Opinions Regarding Medication Costs in Critically Ill Patients
Hospital Pharmacy - June 2018 - 189
Hospital Pharmacy - June 2018 - 190
Hospital Pharmacy - June 2018 - 191
Hospital Pharmacy - June 2018 - 192
Hospital Pharmacy - June 2018 - 193
Hospital Pharmacy - June 2018 - Detection of HBV, HCV, and Incidence of Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma–Treated Patients
Hospital Pharmacy - June 2018 - 195
Hospital Pharmacy - June 2018 - 196
Hospital Pharmacy - June 2018 - 197
Hospital Pharmacy - June 2018 - 198
Hospital Pharmacy - June 2018 - 199
Hospital Pharmacy - June 2018 - 200
Hospital Pharmacy - June 2018 - Cover3
Hospital Pharmacy - June 2018 - Cover4
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com